Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 6/20 | 0.43 |
| ▸ | CDK4 | P11802 | 3/20 | 0.40 |
| ▸ | CCND1 | P24385 | 3/20 | 0.40 |
| ▸ | CCND2 | P30279 | 3/20 | 0.40 |
| ▸ | CCND3 | P30281 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 9/20 | 0.39 |
| ▸ | RORA | P35398 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | RORB | Q92753 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17807791 | 0.80 | CASR (0.45) | MAOBCASR | |
| SCHEMBL18898516 | 0.78 | MAOB (0.34) | BTKCDK4CCND1CCND2CCND3 | |
| SCHEMBL4795814 | 0.74 | ALDH1A1 (0.46) | BTKCDK4CCND1CCND2CCND3 | |
| SCHEMBL12125239 | 0.72 | HTR2A (0.47) | — | |
| SCHEMBL10080931 | 0.69 | NOTUM (0.42) | — | |
| SCHEMBL22538172 | 0.69 | BTK (0.64) | BTKCDK4CCND1CCND2CCND3 | |
| SCHEMBL19546070 | 0.69 | RORA (0.40) | MAOBRORARORCRORB | |
| SCHEMBL22822495 | 0.68 | ALDH1A1 (0.45) | MAOBRORARORCRORB | |
| SCHEMBL25752342 | 0.68 | ALDH1A1 (0.50) | BTKMAOBCASRRORARORC | |
| SCHEMBL22419361 | 0.68 | CASR (0.44) | BTKCDK4CCND1CCND2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177855-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177855-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BTK 1273/4885CDK4 238/4885CCND1 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.